Hemophilia is a rare genetic blood disorder that affects approximately 250 patients in Albania. Inherited primarily from the mother, hemophilia manifests in males, while females are carriers of the condition. The deficiency of factor 8 and 9 in their bodies prevents their blood from clotting properly, often resulting in frequent and prolonged bleeding episodes.
 |
| A man with arms with signs of hemophilia (archive) |
Apart from administering factor replacement therapy in cases of trauma, Albania has embarked on implementing prophylactic therapy for children with hemophilia over the past two years, offering them the opportunity for a more normal life.
Living with hemophilia requires patients to be trained in administering their own first aid with clotting factors to stop bleeding episodes.
While hemophilia may not be diagnosed in cases of mild severity, signs often manifest in advanced stages, sometimes even in childhood. In Albania, approximately 1 in 5000 babies are born with hemophilia. Affected patients are dispersed throughout the country.
The introduction of prophylactic therapy represents a significant advancement in the management of hemophilia, aiming to prevent bleeding episodes rather than merely treating them reactively. This proactive approach not only improves the quality of life for patients but also reduces the burden on healthcare resources associated with managing complications from untreated or poorly managed hemophilia.
In addition to medical interventions, raising awareness about hemophilia is crucial to ensure early diagnosis and access to appropriate care. Support networks and education for patients and their families play a vital role in navigating the challenges posed by this lifelong condition.
With ongoing efforts in research, healthcare infrastructure development, and public education, Albania continues to make strides in improving the lives of those affected by hemophilia, striving towards a future where individuals with this condition can lead fulfilling and productive lives.